August 2024 Newsletter
Welcome to the monthly Crown Bioscience newsletter. Discover some of our monthly highlights to keep up to date with recent developments and to learn more about our services. Don't forget to follow us on LinkedIn to avoid missing our daily updates!
We are delighted to announce a strategic partnership with Clinical Trial & Consulting Services (CTI), a renowned global full-spectrum research service provider, to bolster oncology-focused consulting services.
This collaboration unites decades of expertise from both organizations in oncology drug discovery and development, leveraging Crown Bioscience’s preclinical and translational models and CTI’s well-established track record in the clinical and regulatory space.
Customers will benefit from the combined expert guidance, supporting the transition of oncology compounds from discovery through early-phase global trials more rapidly and effectively.
MuScreen provides a cost-effective screening platform, with a free vehicle arm and shared cost of the positive control arm. Register by September 13th to fast-track your in vivo preclinical immunotherapy development.
Looking to evaluate your NSCLC immunotherapies potential to overcome drug resistance? Discover the HCC827 validated CDX model, an adenocarcinoma cell line that contains patient-relevant activating EGFR mutation in exon 19.
Join us at the World Clinical Biomarkers & CDx Summit Booth 36! We’re showcasing our integrated approach to advancing drug development. Schedule a meeting with our team to see how we can be your comprehensive partner in drug development.
Discover how customized biomarker development and validation, using FFPE tissue samples on the Simple Western Size platform, is a valuable tool to support biomarker research.
Explores the dynamic intersection of technology and biology, where in vitro tools and OMICs applications unravel mechanisms of action, drug discovery, and clinical translation.
Join our colleagues for CICON24, from September 8-11, 2024, to discuss the latest strides in the dynamic field of cancer immunotherapy. Meet with us to discover how you can leverage our extensive experience in oncology and immuno-oncology research.
Join us and your industry peers for our UK symposium "Translational Solutions to Target Oncology Drug Resistance", on 25th September, 2024! We'll explore how integrating cutting-edge tools, including patient-derived systems and I/O co-culture assays, can accelerate the development of therapies aimed at overcoming oncology drug resistance.
? 2024 Crown Bioscience
Crown Bioscience, Inc. 16550 West Bernardo Drive, Building 5, Suite 525, San Diego, CA 92127, United States